Adaptive immunity maintains occult cancer in an equilibrium state

Nature

Volumn 450, Issue 7171, 2007, Pages 903-907

  Koebel, Catherine M ^a   Vermi, William ^a,b   Swann, Jeremy B ^c,d   Zerafa, Nadeen ^c   Rodig, Scott J ^e   Old, Lloyd J ^f   Smyth, Mark J ^c,d   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SPEDALI CIVILI   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; EXPERIMENTAL STUDY; IMMUNE RESPONSE; IMMUNE SYSTEM; RODENT; WILD POPULATION;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNE SYSTEM; IMMUNOGENICITY; MOUSE; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; TUMOR CELL;

MUS;

EID: 36849010167     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06309     Document Type: Article

References (35)

1. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
2. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
3. Street, S. E., Trapani, J. A., MacGregor, D. & Smyth, M. J. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J. Exp. Med. 196, 129-134 (2002).
4. Smyth, M. J. et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200, 1325-1335 (2004).
5. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
6. Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nature Immunol. 6, 722-729 (2005).
7. Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
8. Smyth, M. J., Dunn, G. P. & Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1-50 (2006).
9. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature Rev. Immunol. 6, 836-848 (2006).
10. MacKie, R. M., Reid, R. & Junor, B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348, 567-568 (2003).
11. Qin, Z., Kim, H. J., Hemme, J. & Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon γ receptor-dependent foreign body reaction. J. Exp. Med. 195, 1479-1490 (2002).
12. Brown, D. C. & Gatter, K. C. Ki67 protein: the immaculate deception? Histopathology 40, 2-11 (2002).
13. Bullwinkel, J. et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J. Cell. Physiol. 206, 624-635 (2006).
14. Weinhold, K. J., Goldstein, L. T. & Wheelock, E. F. Tumour-dormant states established with L5178Y lymphoma cells in immunised syngeneic murine hosts. Nature 270, 59-61 (1977).
15. Siu, H., Vitetta, E. S., May, R. D. & Uhr, J. W. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J. Immunol. 137, 1376-1382 (1986).
16. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
17. Ohtani, H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 7, 4-12 (2007).
18. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538-18543 (2005).
19. Sakr, W. A. & Partin, A. W. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 57, 115-120 (2001).
20. Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127, 1023-1028 (1997).
21. Mutter, G. L. et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 61, 4311-4314 (2001).
22. Bach, P. B. et al. Computed tomography screening and lung cancer outcomes. J. Am. Med. Assoc. 297, 953-961 (2007).
23. Balkwill, F. & Coussens, L. M. Cancer: an inflammatory link. Nature 431, 405-406 (2004).
24. Lin, W. W. & Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175-1183 (2007).
25. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
26. Dialynas, D. P. et al. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol. Rev. 74, 29-56 (1983).
27. Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D. & Waldmann, H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312, 548-551 (1984).
28. Schreiber, R. D., Hicks, L. J., Celada, A., Buchmeier, N. A. & Gray, P. W. Monoclonal antibodies to murine γ-interferon which differentially modulate macrophage activation and antiviral activity. J. Immunol. 134, 1609-1618 (1985).
29. Ho, E. L. et al. Costimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169, 3667-3675 (2002).
30. Koo, G. C. & Peppard, J. R. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3, 301-303 (1984).
31. Kayagaki, N. et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163, 1906-1913 (1999).
32. Wysocka, M. et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25, 672-676 (1995).
33. Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nature Immunol. 6, 722-729 (2005).
34. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 4, 661-668 (2000).
35. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).